一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Journal of Database Management >>article
Journal of Database Management

Journal of Database Management

IF: 1.3
Download PDF

Teneligliptin: Heralding Change in Type 2 Diabetes

Published:31 March 2016 DOI: 10.4236/JDM.2016.62012
M. Maladkar,?Srividya Sankar,?K. Kamat

Abstract

“Sweet is Sweet but until it is not too Sweet”. As the sweet spoon of diabetes challenges the global population, diabetic organizations across the globe call for unanimous resonance of Diabetes Voice to tackle diabetes with healthy living. With the discovery of new pathophysiology associated with diabetes, patients are gaining access to the newer therapeutic classes. Teneligliptin, a third generation DPP-4 inhibitor exhibits unique “J-shaped” structure with “anchor-lock domain” mechanism which provides potent & long duration of action. It acts like an insulin/glucagon modulator controlling blood glucose over 24 hours. It is effective in tackling short-term glycemic fluctuations and improvement in β-cell parameters is observed soon after treatment. Half-life of 26.9 hours ensures once a day administration. Because the metabolites of this drug are eliminated via renal and hepatic excretion, no dose adjustment is necessary in patients with renal impairment. Improvement in lipid profile, LV function, adiponectin levels & natriuretic effect is among the added pleiotropic benefits. With the effective glycemic control & capability for improvement in β-cell function, Teneligliptin promises to be a preferable antidiabetic agent with long-term efficacy & safety in patients with type 2 diabetes. The objective of this paper is to provide a comprehensive datum analysis of Teneligliptin in the management of type 2 diabetes. It summarizes the unique pharmacodynamic & pharmacokinetic advantages of Teneligliptin and additionally its pleiotropic benefits of cardioprotection. It provides a comprehensive comparison of Teneligliptin vis-a-vis other gliptins in the class & provides a concise summary of all clinical trials till the date with Teneligliptin monotherapy & combination with other antidiabetic drugs.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Teneligliptin 760937-92-6 C22H30N6OS 192 suppliers $44.00-$1815.00

Similar articles

IF:0

Teneligliptin: DPP-4 inhibitor in the treatment of type II Diabetes Mellitus

International Journal of Phytopharmacy K. Danao, M. Shende,etc Published: 30 August 2017
IF:13

Linagliptin: in type 2 diabetes mellitus.

Drugs Lesley J Scott,etc Published: 26 March 2011
IF:13

Dapagliflozin: A Review in Type 2 Diabetes.

Drugs Sohita Dhillon,etc Published: 1 July 2019
太白县| 上犹县| 乌拉特后旗| 建瓯市| 宜兰县| 安阳市| 静海县| 修水县| 承德市| 会昌县| 东海县| 墨江| 来凤县| 河西区| 英超| 永昌县| 泗洪县| 江陵县| 长沙市| 清水河县| 永宁县| 昔阳县| 留坝县| 威宁| 平遥县| 自治县| 宽城| 台东市| 酉阳| 莆田市| 桓仁| 伊川县| 黄浦区| 溧水县| 福泉市| 北海市| 武宁县| 彭山县| 永康市| 兴安盟| 固阳县|